Although the majority of heart transplant recipients have a satisfactory heart rate, a substantial number require a permanent pacemaker. In 7 of 46 heart transplant patients at our institution symptomatic bradycardia developed, necessitating implantation of a transvenous pacemaker. The average time from heart transplantation to pacer insertion was 25 days. The average donor age, ischemic period, and crossclamp time was 28 years, 182 minutes, and 113 minutes, respectively. A long aortic crossclamp time (greater than 83 minutes) increased the risk for conduction abnormalities in the sinoatrial node. No patient had rejection before the pacer implantation. Five of the seven patients continue to be paced a significant amount of a 24-hour period. Only one patient has had considerable improvement in 3 years, requiring pacing only 3% of a monitored 24-hour period. This patient had the longest ischemic time and the most rejection episodes after implantation of the pacemaker. One patient was paced 100% until a second heart transplantation was done, without a subsequent need for pacing. The other five patients' hearts continue to be paced between 80% and 100% of a 24-hour monitored period. The donor intrinsic heart rates of these five patients produce symptomatic bradycardia. The success of AAI pacing in all patients indicates normal conduction below the sinoatrial node. The injury or dysfunction resulting in bradycardia was isolated to the sinoatrial node. Long-term follow-up in three patients (greater than 3 years) shows the need for pacing to be intermittent but long term. Most patients never fully recover from symptomatic bradycardia.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|
Bone Marrow Transplant
January 2025
Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
J Cardiothorac Vasc Anesth
January 2025
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA.
Vasoplegia is a pathophysiologic state of hypotension in the setting of normal or high cardiac output and low systemic vascular resistance despite euvolemia and high-dose vasoconstrictors. Vasoplegia in heart, lung, or liver transplantation is of particular interest because it is common (approximately 29%, 28%, and 11%, respectively), is associated with adverse outcomes, and because the agents used to treat vasoplegia can affect immunosuppressive and other drug metabolism. This narrative review discusses the pathophysiology, risk factors, and treatment of vasoplegia in patients undergoing heart, lung, and liver transplantation.
View Article and Find Full Text PDFBMJ Open
January 2025
Deakin Health Economics, Institute for Health Transformation, Deakin University, Melbourne, Victoria, Australia.
Objective: To assess the prevalence and trends of chronic kidney disease (CKD) in Western Australia (WA) from 2010 to 2020 using linked pathology data.
Design: A retrospective observational cohort study using linked de-identified data from WA pathology providers, hospital morbidity records and mortality records.
Setting: A Western Australian population-based study.
Environ Pollut
January 2025
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Electronic address:
Microplastics (MPs) have been found to interfere with the gut microbiota and compromise the integrity of the gut barrier. Excessive exposure to MPs markedly elevates the risk of cardiovascular disease, yet their influence on hypertension remains elusive, calling for investigation into their potential impacts on blood pressure (BP) regulation. In the present study, an increase in the concentration of MPs was observed in the fecal samples of individuals suffering from hypertension, as compared to the controls.
View Article and Find Full Text PDFAm J Transplant
January 2025
Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
There is substantial variation in access to transplantation across the United States that is not entirely explained by the availability of donor organs. Barriers to transplantation and variation in care among patients with end-stage organ disease exist prior to patients' placement on a transplant waiting list as well as following waitlist placement. However, there are currently no national data available to examine rates and variations in key care processes related to pre-listing, including transplant referral, evaluation, or candidate selection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!